Actelion joins forces with Trophos to further advance olesoxime to the market once results of the MitoTarget clinical study are known.
Actelion obtains option to acquire privately-held Trophos Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be furth

